Stockscreener 앱 받기
141.77
2.72%
3.76
시간 외 거래:
141.78
0.010
+0.01%
전일 마감가:
$138.01
열려 있는:
$139.3
하루 거래량:
173.59K
Relative Volume:
0.66
시가총액:
$2.03B
수익:
$1.30M
순이익/손실:
$-49.30M
주가수익비율:
-34.01
EPS:
-4.1688
순현금흐름:
$-29.10M
1주 성능:
+14.19%
1개월 성능:
-4.35%
6개월 성능:
+68.83%
1년 성능:
+267.09%
1일 변동 폭
$139.30
$146.15
1주일 범위
$120.61
$146.15
52주 변동 폭
$34.57
$161.38
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
141.77 | 1.98B | 1.30M | -49.30M | -29.10M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Mizuho | Outperform |
| 2025-12-05 | 개시 | BTIG Research | Buy |
| 2025-12-04 | 개시 | Craig Hallum | Buy |
| 2025-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics Inc (PVLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palvella Therapeutics Inc (PVLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PVLA|Palvella Therapeutics Inc|Price:138.010|Chg%:-5.195 - TradingKey
TradingKey - TradingKey
Palvella Therapeutics, Inc. Revenue Breakdown – NASDAQ:PVLA - TradingView
Palvella Therapeutics Inc (PVLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palvella Therapeutics Inc (PVLA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to revenue forward of Palvella Therapeutics, Inc. – FWB:PI6 - TradingView
H.C. Wainwright reiterates Palvella Therapeutics stock rating at buy - Investing.com UK
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
H.C. Wainwright reiterates Palvella Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270 - Moomoo
Oppenheimer Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210 - Moomoo
BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215 - Moomoo
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Palvella Therapeutics (PVLA) Sees Significant Decline - GuruFocus
Palvella Therapeutics (PVLA) COO exercises options, then sells 4,302 shares - Stock Titan
Palvella Therapeutics Soars On Key FDA Review Break - TipRanks
Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $642,194.57 - Bitget
Palvella Therapeutics Files New Drug Application for QTORIN - harianbasis.co
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress - TipRanks
Palvella Therapeutics Files Initial NDA for QTORIN Gel - sekbernews.id
Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN - Yahoo Finance
Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash - TradingView
Palvella Therapeutics (PVLA) Proxy filing Summary - Quartr
Palvella Therapeutics (PVLA) Faces Pullback After Recent Gains – Key Support Levels in FocusRevenue Growth Stocks - dars.gov.et
Palvella Therapeutics Inc. (PVLA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Palvella Adds Rare-Disease Executive to Board Ahead of Launch - MyChesCo
PVLAPalvella Therapeutics Inc Volatility & Greeks - Finviz
Price to book forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA) - The Globe and Mail
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Palvella Therapeutics Adds Industry Veteran to Board - The Globe and Mail
Palvella Therapeutics (NASDAQ: PVLA) director reports zero share stake - Stock Titan
Palvella Therapeutics Adds Rare Disease Executive Matt Pauls to Board of Directors - citybiz
Palvella Therapeutics, Inc. Files Form 8-K: Key Company Details, Stock Info, and Contact Information (June 2026) - Minichart
Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics appoints Matt Pauls to board of directors - Investing.com
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail
Palvella Therapeutics Appoints Accomplished Rare Disease - GlobeNewswire
Matthew Pauls joins Palvella Therapeutics (PVLA) board with 6,000-share option grant - Stock Titan
Palvella Therapeutics stock hits 52-week high at 151.36 USD - Investing.com
Palvella Therapeutics stock hits 52-week high at 151.36 USD By Investing.com - Investing.com Nigeria
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000E Index - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell Microcap Index - marketscreener.com
Palvella submits FDA NDA for QTORIN gel - grafa.com
Palvella submits first module of NDA for rare skin disease therapy - Investing.com
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - The Manila Times
Palvella Therapeutics Submits First Rolling NDA Module for QTORIN Rapamycin in Microcystic Lymphatic Malformations - Quiver Quantitative
Palvella Therapeutics Submits First Module of Rolling New - GlobeNewswire
Palvella Therapeutics Inc (PVLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):